The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?
作者信息
Créhange Gilles, Conroy Thierry
机构信息
1 Department of Radiation Oncology, Centre Georges François Leclerc, University of Burgundy, Dijon, France ; 2 Medical imaging group, IMAC CNRS 6306, University of Burgundy, Esplanade Erasme, Dijon, France ; 3 Department of Medical Oncology, Institut de Cancérologie de Lorraine, 6 Avenue de Bourgogne, 54519 Vandoeuvre-lès-Nancy, France ; 4 EA 4360, Lorraine University, 9 Avenue de la Forêt de Haye, 54505 Vandœuvre-lès-Nancy, France.
出版信息
J Thorac Dis. 2016 Jun;8(6):1014-8. doi: 10.21037/jtd.2016.03.74.
Abstract
摘要
相似文献
1
The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?
J Thorac Dis. 2016 Jun;8(6):1014-8. doi: 10.21037/jtd.2016.03.74.
2
High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome.
Dis Esophagus. 2010 Apr;23(3):244-52. doi: 10.1111/j.1442-2050.2009.00999.x. Epub 2009 Jul 31.
3
Prediction of survival by tumor area on endosonography after definitive chemoradiotherapy for locally advanced squamous cell carcinoma of the esophagus.
Digestion. 2014;90(2):98-107. doi: 10.1159/000365073. Epub 2014 Sep 4.
4
Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
J Surg Oncol. 2014 Apr;109(5):472-7. doi: 10.1002/jso.23514. Epub 2013 Dec 2.
5
[Neoadjuvant chemoradiotherapy or chemotherapy for locally advanced esophageal cancer?].
Chirurg. 2020 May;91(5):379-383. doi: 10.1007/s00104-020-01150-6.
6
Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer.
Esophagus. 2019 Oct;16(4):402-407. doi: 10.1007/s10388-019-00680-1. Epub 2019 Jun 20.
7
[Biomarkers of predicting response to neoadjuvant chemoradiotherapy in esophageal cancer].
Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Sep;16(9):805-10.
8
Role of definitive chemoradiotherapy using docetaxel and 5-fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study.
Dis Esophagus. 2016 Nov;29(8):1115-1120. doi: 10.1111/dote.12433. Epub 2015 Oct 15.
9
Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
J Thorac Cardiovasc Surg. 2018 Jun;155(6):2710-2721.e3. doi: 10.1016/j.jtcvs.2018.01.086. Epub 2018 Feb 15.
10
Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients.
World J Surg Oncol. 2018 Jul 14;16(1):141. doi: 10.1186/s12957-018-1444-0.
引用本文的文献
1
Comparison between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Their Effectiveness in Esophageal Cancer Treatment: A Retrospective Single Institution Study.
J Oncol. 2020 Mar 20;2020:6582341. doi: 10.1155/2020/6582341. eCollection 2020.
2
Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer.
Ann Surg Oncol. 2019 Apr;26(4):986-995. doi: 10.1245/s10434-019-07181-6. Epub 2019 Feb 4.
本文引用的文献
1
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.
J Clin Oncol. 2016 Feb 10;34(5):427-35. doi: 10.1200/JCO.2015.63.1671. Epub 2015 Dec 7.
2
Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer.
Br J Cancer. 2015 Aug 11;113(4):603-10. doi: 10.1038/bjc.2015.258. Epub 2015 Jul 23.
3
Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer.
Radiother Oncol. 2015 Jan;114(1):91-5. doi: 10.1016/j.radonc.2014.12.005. Epub 2015 Jan 24.
4
Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer.
Radiat Oncol. 2014 Aug 29;9:191. doi: 10.1186/1748-717X-9-191.
5
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.
J Clin Oncol. 2014 Sep 20;32(27):2940-50. doi: 10.1200/JCO.2013.53.5633.
6
Dosimetric benefits of IMRT and VMAT in the treatment of middle thoracic esophageal cancer: is the conformal radiotherapy still an alternative option?
J Appl Clin Med Phys. 2014 May 8;15(3):93–101. doi: 10.1120/jacmp.v15i3.4641.
7
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18.
8
Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.
J Clin Oncol. 2014 Feb 10;32(5):385-91. doi: 10.1200/JCO.2013.51.2186. Epub 2014 Jan 13.
9
Reduced lung dose during radiotherapy for thoracic esophageal carcinoma: VMAT combined with active breathing control for moderate DIBH.
Radiat Oncol. 2013 Dec 20;8:291. doi: 10.1186/1748-717X-8-291.
10
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.
Ann Oncol. 2013 Nov;24(11):2844-9. doi: 10.1093/annonc/mdt339. Epub 2013 Aug 23.
Zotero 插件